INO
Price
$5.55
Change
-$0.10 (-1.77%)
Updated
Oct 4 closing price
ORMP
Price
$2.35
Change
-$0.06 (-2.49%)
Updated
Oct 4 closing price
33 days until earnings call
Ad is loading...

INO vs ORMP

Header iconINO vs ORMP Comparison
Open Charts INO vs ORMPBanner chart's image
Inovio Pharmaceuticals
Price$5.55
Change-$0.10 (-1.77%)
Volume$370.12K
CapitalizationN/A
Oramed Pharmaceuticals
Price$2.35
Change-$0.06 (-2.49%)
Volume$77.57K
CapitalizationN/A
View a ticker or compare two or three
INO vs ORMP Comparison Chart
Loading...
INO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
INO vs. ORMP commentary
Oct 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INO is a StrongSell and ORMP is a StrongSell.

COMPARISON
Comparison
Oct 07, 2024
Stock price -- (INO: $5.55 vs. ORMP: $2.35)
Brand notoriety: INO: Notable vs. ORMP: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INO: 126% vs. ORMP: 72%
Market capitalization -- INO: $152.15M vs. ORMP: $99.48M
INO [@Biotechnology] is valued at $152.15M. ORMP’s [@Biotechnology] market capitalization is $99.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INO’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • INO’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, both INO and ORMP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INO’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • INO’s TA Score: 5 bullish, 4 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INO is a better buy in the short-term than ORMP.

Price Growth

INO (@Biotechnology) experienced а -5.29% price change this week, while ORMP (@Biotechnology) price change was -5.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was -5.77%.

Reported Earning Dates

INO is expected to report earnings on May 08, 2024.

ORMP is expected to report earnings on Nov 08, 2024.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INO($152M) has a higher market cap than ORMP($99.5M). ORMP YTD gains are higher at: 1.732 vs. INO (-9.314). ORMP has higher annual earnings (EBITDA): 25.5M vs. INO (-118.07M). ORMP has more cash in the bank: 153M vs. INO (110M). ORMP has less debt than INO: ORMP (486K) vs INO (13M). INO has higher revenues than ORMP: INO (592K) vs ORMP (0).
INOORMPINO / ORMP
Capitalization152M99.5M153%
EBITDA-118.07M25.5M-463%
Gain YTD-9.3141.732-538%
P/E RatioN/A4.78-
Revenue592K0-
Total Cash110M153M72%
Total Debt13M486K2,675%
FUNDAMENTALS RATINGS
INO vs ORMP: Fundamental Ratings
INO
ORMP
OUTLOOK RATING
1..100
5515
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9854
PRICE GROWTH RATING
1..100
6573
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (54) in the Pharmaceuticals Other industry is in the same range as INO (61) in the Medical Specialties industry. This means that ORMP’s stock grew similarly to INO’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that ORMP’s stock grew similarly to INO’s over the last 12 months.

ORMP's SMR Rating (54) in the Pharmaceuticals Other industry is somewhat better than the same rating for INO (98) in the Medical Specialties industry. This means that ORMP’s stock grew somewhat faster than INO’s over the last 12 months.

INO's Price Growth Rating (65) in the Medical Specialties industry is in the same range as ORMP (73) in the Pharmaceuticals Other industry. This means that INO’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (99) in the Pharmaceuticals Other industry is in the same range as INO (100) in the Medical Specialties industry. This means that ORMP’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INOORMP
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 21 days ago
80%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
INO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASRE0.130.01
+4.10%
ASTRA ENERGY INC.
ATDRY2.810.04
+1.44%
Auto Trader Group Plc.
KYOCY11.720.04
+0.34%
Kyocera Corp.
ADYEY14.82-0.08
-0.54%
Adyen N.V.
IPOOF1.55-0.02
-1.02%
InPlay Oil Corp.